Spectrum Pharma (SPPI) Tops Q3 EPS by 19c

Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.22), $0.19 better than the analyst estimate of ($0.41).

“Spectrum has an expanding pipeline, significant near-term milestones, solid capitalization and a highly focused team,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “In December, we look forward to results from Cohort 1 of our ZENITH20 study investigating poziotinib in lung cancer patients with hard-to-treat mutations. We recently submitted our BLA for ROLONTIS to the FDA, a key milestone, as we continue to execute on our strategic priorities.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• HawkEye 360 wins NRO contract for commercial RF data services
• QT Imaging reports 116% revenue jump in first half of 2026